Fluticasone furoate and vilanterol inhaler effectiveness
Pro Research Analysisby 
Searched over 200M research papers
Fluticasone Furoate and Vilanterol Inhaler Effectiveness in Asthma and COPD
Effectiveness in Asthma: Pulmonary Function and Symptom Control
Fluticasone furoate and vilanterol, delivered as a once-daily inhaler, have shown significant improvements in lung function and asthma control for patients with persistent or symptomatic asthma. Multiple studies found that this combination increases forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF) compared to fluticasone furoate alone or fluticasone propionate, and is as effective as twice-daily fluticasone propionate/salmeterol combinations 2567+1 MORE. In real-world clinical practice, patients starting fluticasone furoate/vilanterol were more likely to achieve better asthma control test (ACT) scores than those on usual care, with improvements sustained over 12 months . The combination also reduced the risk of severe asthma exacerbations compared to fluticasone furoate alone 579. Safety profiles were generally favorable, with no significant increase in serious adverse events 2679.
Effectiveness in COPD: Exacerbation Reduction and Lung Function
For chronic obstructive pulmonary disease (COPD), fluticasone furoate/vilanterol inhalers have demonstrated improved pulmonary function and reduced exacerbation rates compared to placebo, fluticasone furoate alone, or vilanterol alone 110. In phase 3 and real-world studies, once-daily use led to better lung function and fewer moderate or severe exacerbations than usual care, without an increased risk of serious adverse events such as pneumonia 110. Compared to other inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combinations, fluticasone furoate/vilanterol was as effective or more effective, and the once-daily dosing may help improve adherence 110.
Single-Inhaler Triple Therapy: Fluticasone Furoate/Umeclidinium/Vilanterol
When combined with umeclidinium (a long-acting muscarinic antagonist), the triple therapy of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) further improves outcomes for COPD patients. Studies show that this single-inhaler triple therapy leads to greater improvements in FEV1, health status (as measured by the COPD Assessment Test, CAT), and reduced exacerbation rates compared to dual therapies or other triple therapy combinations 34. Real-world data confirm significant and clinically meaningful improvements in symptoms and lung function, with low rates of exacerbations and good safety profiles . These benefits were observed regardless of prior exacerbation history, challenging current guidelines that restrict triple therapy to patients with frequent exacerbations .
Safety and Tolerability
Across asthma and COPD studies, fluticasone furoate/vilanterol inhalers were generally well tolerated. The most common side effects were mild, such as oral candidiasis and cough, and the risk of serious adverse events was similar to other ICS/LABA combinations 1267+2 MORE. Some studies noted a slight increase in pneumonia risk with long-term use, consistent with other inhaled corticosteroids, but no significant increase in cardiac events or other serious complications was observed 1567+1 MORE.
Convenience and Adherence
The once-daily dosing of fluticasone furoate/vilanterol is a key advantage, as it may improve patient adherence compared to twice-daily regimens. Improved adherence is linked to better disease control and fewer exacerbations in both asthma and COPD 1247+1 MORE.
Conclusion
Fluticasone furoate and vilanterol inhalers are effective and generally well tolerated for both asthma and COPD. They improve lung function, reduce exacerbations, and offer the convenience of once-daily dosing, which may enhance adherence and overall disease management. The combination is as effective as, or superior to, other commonly used inhaled therapies, making it a strong option for patients needing maintenance treatment for asthma or COPD.
Sources and full results
Most relevant research papers on this topic
Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: A systematic review with meta-analysis.
Fluticasone furoate-vilanterol combination improves pulmonary function and reduces asthma exacerbations, but differences may not be clinically significant.
DOI